Ze'ev:
I would be happy to leave it as a marketing issue, but people here have not (you included). You will see when the study is released that it was conducted with a major university with the proper controls. You choose to ignore the statistical significance arguments but those will have to wait until publishing of the study to be argued effectively. If two articles about "medical vampires" can be published in the NEJM and Tremacamra - a bioengineered ICAM protein, can be published in JAMA, it is not a stretch to put in a study about Zicam and to expect it to be published.
There are differences between the Quigley preparations and Zicam and actually that is precisely why Zicam will be preferable: lower dose delivered effectively at the site of infection. Again, a little DD on the part of the shorts might be in order. In addition, the matrix and method of application will probably have other applications. Recently, inhalants have been used with a similar methods of administration and work locally in the lung when breathed in (eg, steroids for lung disease) and are now better accepted this way rather than systemically and have fewer side effects.
Indeed, simple silver nitrate was the answer to the question about using an ionic solution as an antibiotic, and the point was that some simple compounds, when used effectively, can be medically helpful, and it can be proven statistically.
Analogy 1: I am about to suture a wound in your hand. Would you like the lidocaine administered IV, intramuscularly or at the site of the incision? Now let's say instead you have an arrhythmia. Would you like the lidocaine IM or IV? Shouldn't I give you a different dose for antiarrhythmia than for local analgesia.
Analogy 2 : If you have scurvy and I give you vitamin C, is that quackery? If I give you vitamin B12 if you have atrophic gastritis and pernicious anemia, is that snake oil?
Bottom line: The study will stand on its own but you are premature to use innuendo such as "snake oil". Just because Zinc ion mimics the nasal cell ICAM does not make it snake oil. The mechanism of rhinoviruses and ICAM is well-documented. Again, more dd could be done by shorters but it is easier to call us "shills". One syllable and no work, what more could Wexler want?
Anyway, I will leave you alone since you state that you just want to deal with the financial part of it as a stock. I think Dan has dealt with that and the present orders speak for themselves in that regard, but I personally see efficacy and respectability tied to continuing success of the Zicam and I am extremely sure that is also the case with GelTech and GUMM. Specifically, that is where Quigley broke down, not to mention they slashed their advertising budget at the same time. |
